for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

FACTBOX-EU tries to catch-up after U.S., UK spend billions to secure coronavirus vaccines

 (Adds AstraZeneca's Canada and Thailand deals, RDIF deals with Uzbekistan, Egypt, India, Nepal and Brazil; Updates Johnson & Johnson's EU
agreement)
    Oct 12 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of
experimental coronavirus vaccines. The European Union also struck its first supply deal with AstraZeneca in August, and has signed two more
with Johnson & Johnson and Sanofi since then. 
    The following is a list of supply deals that give some countries a guarantee of a limited number of doses:
    
 COUNTRY/REGIO  COMPANY                      DEAL TERM           NO OF DOSES                      DELIVERY DATE                STORY LINK
 N U.S.           Moderna Inc                  $1.53 bln           100 mln + option for additional  Not specified                            
                                                                 400 mln                                                       
 U.S.           Pfizer Inc         and       $1.95 bln           100 mln + option for 500 mln     By October                               
                BioNTech SE                                      more                                                          
 U.S.           AstraZeneca Plc              $1.2 bln            300 mln                          By October                               
 U.S.           Novavax Inc                  $1.6 bln            100 mln                          By January 2021                          
 U.S.           Johnson & Johnson            Over $1 bln         100 mln + 200 mln more under     Not Specified                            
                                                                 subsequent agreement                                          
 U.S.           Sanofi SA           and      $2.1 bln            100 mln + option for 500 mln     Not Specified                            
                GlaxoSmithKline Plc                              more                                                          
 EU             AstraZeneca                  336 mln euros       At least 300 mln + 100 mln       Not specified                            
                                             ($396 mln)          additional                                                    
 EU             Johnson & Johnson            Undisclosed         200 mln + 200 mln additional     Not Specified                            
 EU             Sanofi SA and                324 mln euros       300 mln                          Not Specified                            
                GlaxoSmithKline              ($384 mln)                                                                        
 EU             Moderna                      In talks            80 mln                           Not Specified                            
 EU             CureVac                      In talks            225 mln + option for 180 mln     Not Specified                            
                                                                 additional                                                    
 EU             BioNTech/ Pfizer             Concluded           200 mln + 100 mln additional     Not Specified                            
                                             exploratory talks                                                                 
 EU             ReiThera                     In early talks      Not specified                    Not specified                            
 Italy,         AstraZeneca                  750 mln euros       300 mln + 100 mln additional     Not Applicable                           
 Germany, the                                ($843 million)                                                                    
 Netherlands and France UK             Johnson & Johnson            Non-profit basis    30 mln + option for up to 22     Not specified                            
                                             for emergency use;  mln more option to purchase additional doses                                                                  
 UK             Novavax                      Not specified       60 mln, and plan for a           By early 2021; phase 3                   
                                                                 late-stage trial in UK with      trial in Q3 2020             
                                                                 govt support                                                  
 UK             Valneva                      "Multi-million      60 mln + 40 mln additional       Not Applicable                           
                                             pound" investment                                                                 
 UK             Sanofi          ,            Financial terms     Up to 60 mln                     Not Applicable                           
                GlaxoSmithKline              undisclosed                                                                       
 UK             Pfizer and BioNTech          Financial terms     30 mln                           Not Applicable                           
                                             undisclosed                                                                       
 UK             AstraZeneca                  65.5 mln pounds in  Up to 30 mln (part of a          September                                
                                             total               commitment to deliver 100 mln                                 
                                                                 total)                                                        
 Canada         Pfizer and BioNTech          Financial details   Not specified                    Over the course of 2021                  
                                             not disclosed                                                                     
 Canada         Moderna                      Not specified       Not specified                    Not Specified                            
 Canada         Johnson & Johnson            Not specified       Up to 38 mln                     Not specified                            
 Canada         AstraZeneca                  Not specified       Up to 20 mln                     Not specified                            
 Canada         Novavax                      Not specified       Up to 76 mln                     Q2 of 2021                               
 Japan          Moderna                      In talks            40 mln or more, to be            H1 of 2021                               
                                                                 distributed by Takeda                                         
 Japan          Pfizer and BioNTech          Financial details   120 mln                          H1 of 2021                               
                                             were not disclosed                                                                
 Japan          Johnson & Johnson            In talks            Not Applicable                   Not Applicable                           
 Japan          AstraZeneca                  Co-production with  120 mln                          First 30 mln expected by                 
                                             JCR Pharma                                           March 2021                   
                                                     , Daiichi Sankyo Biotech and KM Biologics                                                                      
 Japan          Novavax                      Co-production with  250 mln                          Production is yearly                     
                                             Takeda                                               estimate                     
 Europe, Latin  Arcturus Therapeutics        In talks            Not Applicable                   Not Applicable                           
 America and    Holdings Inc Southeast Asia Israel         Arcturus Therapeutics        $275 million        Initial one mln                  Not Applicable                           
                Holdings Inc Israel         Moderna                      Financial terms     Not Applicable                   Not Applicable                           
                                             were not disclosed                                                                
 Indonesia      Sinovac Biotech Ltd          Financial terms     At least 40 mln                  By March 2021                            
                                             were not disclosed                                                                
 China          AstraZeneca                  Produced by         At least 200 mln                 By end 2021                              
                                             Shenzhen Kangtai Biological Products Thailand       AstraZeneca                  Not disclosed       Not disclosed                    Mid-year 2021                            
 Uzbekistan     Russia's sovereign fund,     Not disclosed       Up to 35 million                 Not applicable                           
                RDIF Egypt          RDIF                         Not disclosed       25 million                       Not applicable                           
 India          RDIF                         Not disclosed       100 million                      Not applicable                           
 Nepal          RDIF                         Not disclosed       25 million                       Not applicable                           
 Brazil         Gamaleya Research Institute  Not disclosed       Brazil's Bahia state to get 50   To start in November                     
                and RDIF                                         mln and will conduct Phase 3 clinical trials                                               
 Brazil         AstraZeneca                  $356 mln to buy     100 mln                          December/January                         
                                             and produce the vaccine                                                                           
 Mexico         Gamaleya, RDIF               Financial terms     32 mln                           November                                 
                                             not specified                                                                     
 Mexico,        AstraZeneca                  To produce the      150 mln + up to 250 mln more     First half of 2021                       
 Argentina                                   vaccine for most of Latin America                                                                  
 

($1 = 0.8484 euros)

 (Reporting by Mrinalika Roy, Manojna Madippatla, Trisha Roy and Manas Mishra in Bengaluru, Rocky Swift in Tokyo; Editing by Sriraj
Kalluvila, Shounak Dasgupta, Aditya Soni, Vinay Dwivedi and Ramakrishnan M.)
  

Breakingviews

Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.


Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up